Iterum Therapeutics plc (ITRMF) Non-Current Debt (2018 - 2023)

Iterum Therapeutics has reported Non-Current Debt for 6 years, with the latest figure at $11.5 million in Q4 2023.

• On a quarterly basis, Non-Current Debt rose 13.46% year-over-year to $11.5 million in Q4 2023; TTM through Dec 2023 was $11.5 million, a 13.46% increase from a year earlier, with the FY2023 full-year figure at $11.5 million, up 13.46% from the prior year.
• Non-Current Debt was $11.5 million for Q4 2023 at Iterum Therapeutics, down from $12.5 million in the prior quarter.
• The five-year high for Non-Current Debt was $22.5 million in Q4 2020, with the low at $5.3 million in Q2 2021.
• Average Non-Current Debt over 5 years is $11.5 million, with a median of $10.4 million recorded in 2019.
• The sharpest annual moves came in 2020 and 2021: Non-Current Debt jumped 194.58% in 2020, then plunged 74.49% in 2021.
• Over 5 years, Non-Current Debt stood at $7.6 million in 2019, then surged by 194.58% to $22.5 million in 2020, then plunged by 69.15% to $6.9 million in 2021, then jumped by 45.66% to $10.1 million in 2022, then grew by 13.46% to $11.5 million in 2023.
• The last three Non-Current Debt figures came in at $11.5 million (Q4 2023), $12.5 million (Q3 2023), and $11.7 million (Q2 2023), per Business Quant data.